Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina

Marta E. Szabo, David Haines, Elizabeth Garay, Carlo Chiavaroli, Jean Claude Farine, Patrick Hannaert, A. Berta, Ricardo P. Garay

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Calcium dobesilate possesses antioxidant properties and protects against capillary permeability by reactive oxygen species in the rat peritoneal cavity, but whether a similar action can take place in the diabetic rat retina is unknown. We investigated the oral treatment of diabetic rats with calcium dobesilate on the prevention of free radical-mediated retinal injury induced by ischemia/reperfusion (90 min ischemia followed by 3 min and/or 24 h of reperfusion). Streptozotocin-induced diabetic rats were orally treated with 50 and 100 mg/kg of calcium dobesilate for 10 days (n = 12 in each group). In the first series of studies, calcium dobesilate was found to significantly reduce the maldistribution of ion content in diabetic ischemic/reperfused rat retina. Thus, in diabetic rats treated with 100 mg/kg/day calcium dobesilate, ischemia/reperfusion provoked: (i) 27.5% increase in retinal Na+ content compared to 51.8% in the vehicle-treated group (P <0.05), and (ii) 59.6% increase in retinal Ca2+ content compared to 107.1% in vehicle-treated animals (P <0.05). In the second series of studies, calcium dobesilate was found to significantly protect diabetic rat retina against inhibition of Na+/K+-ATPase and Ca2+/Mg2+-ATPase activities by ischemia/reperfusion (54% and 41% reduction, respectively, with 100 mg/kg of calcium dobesilate) and also against changes in retinal ATP, reduced glutathione (GSH), and oxidized glutathione (GSSG) contents. In the third series of experiments, rats treated with 100 mg/kg of calcium dobesilate reduced the hydroxyl radical signal intensity to 41% (measured by electron paramagnetic resonance), induced by ischemia/reperfusion in diabetic rat retina. Finally, 100 mg/kg calcium dobesilate significantly reduced retinal edema (measured by the thickness of the inner plexiform layer) in diabetic rats. In conclusion, oral treatment with calcium dobesilate significantly protected diabetic rat retina against oxidative stress induced by ischemia/reperfusion. Whether the antioxidant properties of calcium dobesilate explain, at least in part, its beneficial therapeutic effects in diabetic retinopathy deserves further investigation.

Original languageEnglish
Pages (from-to)277-286
Number of pages10
JournalEuropean Journal of Pharmacology
Volume428
Issue number2
DOIs
Publication statusPublished - Oct 5 2001

Fingerprint

Calcium Dobesilate
Retina
Antioxidants
Reperfusion
Ischemia
Glutathione Disulfide
Ca(2+) Mg(2+)-ATPase
Papilledema
Peritoneal Cavity
Electron Spin Resonance Spectroscopy
Capillary Permeability
Therapeutic Uses
Diabetic Retinopathy
Streptozocin
Reperfusion Injury
Hydroxyl Radical

Keywords

  • (Rat)
  • Antioxidant
  • Ca
  • Calcium dobesilate
  • Diabetic retinopathy
  • Ischemia
  • K
  • Na
  • Reperfusion
  • Retina

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Szabo, M. E., Haines, D., Garay, E., Chiavaroli, C., Farine, J. C., Hannaert, P., ... Garay, R. P. (2001). Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. European Journal of Pharmacology, 428(2), 277-286. https://doi.org/10.1016/S0014-2999(01)01196-7

Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. / Szabo, Marta E.; Haines, David; Garay, Elizabeth; Chiavaroli, Carlo; Farine, Jean Claude; Hannaert, Patrick; Berta, A.; Garay, Ricardo P.

In: European Journal of Pharmacology, Vol. 428, No. 2, 05.10.2001, p. 277-286.

Research output: Contribution to journalArticle

Szabo, ME, Haines, D, Garay, E, Chiavaroli, C, Farine, JC, Hannaert, P, Berta, A & Garay, RP 2001, 'Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina', European Journal of Pharmacology, vol. 428, no. 2, pp. 277-286. https://doi.org/10.1016/S0014-2999(01)01196-7
Szabo, Marta E. ; Haines, David ; Garay, Elizabeth ; Chiavaroli, Carlo ; Farine, Jean Claude ; Hannaert, Patrick ; Berta, A. ; Garay, Ricardo P. / Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. In: European Journal of Pharmacology. 2001 ; Vol. 428, No. 2. pp. 277-286.
@article{01340513f44b4bc7a4b2c29e2a2bd43f,
title = "Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina",
abstract = "Calcium dobesilate possesses antioxidant properties and protects against capillary permeability by reactive oxygen species in the rat peritoneal cavity, but whether a similar action can take place in the diabetic rat retina is unknown. We investigated the oral treatment of diabetic rats with calcium dobesilate on the prevention of free radical-mediated retinal injury induced by ischemia/reperfusion (90 min ischemia followed by 3 min and/or 24 h of reperfusion). Streptozotocin-induced diabetic rats were orally treated with 50 and 100 mg/kg of calcium dobesilate for 10 days (n = 12 in each group). In the first series of studies, calcium dobesilate was found to significantly reduce the maldistribution of ion content in diabetic ischemic/reperfused rat retina. Thus, in diabetic rats treated with 100 mg/kg/day calcium dobesilate, ischemia/reperfusion provoked: (i) 27.5{\%} increase in retinal Na+ content compared to 51.8{\%} in the vehicle-treated group (P <0.05), and (ii) 59.6{\%} increase in retinal Ca2+ content compared to 107.1{\%} in vehicle-treated animals (P <0.05). In the second series of studies, calcium dobesilate was found to significantly protect diabetic rat retina against inhibition of Na+/K+-ATPase and Ca2+/Mg2+-ATPase activities by ischemia/reperfusion (54{\%} and 41{\%} reduction, respectively, with 100 mg/kg of calcium dobesilate) and also against changes in retinal ATP, reduced glutathione (GSH), and oxidized glutathione (GSSG) contents. In the third series of experiments, rats treated with 100 mg/kg of calcium dobesilate reduced the hydroxyl radical signal intensity to 41{\%} (measured by electron paramagnetic resonance), induced by ischemia/reperfusion in diabetic rat retina. Finally, 100 mg/kg calcium dobesilate significantly reduced retinal edema (measured by the thickness of the inner plexiform layer) in diabetic rats. In conclusion, oral treatment with calcium dobesilate significantly protected diabetic rat retina against oxidative stress induced by ischemia/reperfusion. Whether the antioxidant properties of calcium dobesilate explain, at least in part, its beneficial therapeutic effects in diabetic retinopathy deserves further investigation.",
keywords = "(Rat), Antioxidant, Ca, Calcium dobesilate, Diabetic retinopathy, Ischemia, K, Na, Reperfusion, Retina",
author = "Szabo, {Marta E.} and David Haines and Elizabeth Garay and Carlo Chiavaroli and Farine, {Jean Claude} and Patrick Hannaert and A. Berta and Garay, {Ricardo P.}",
year = "2001",
month = "10",
day = "5",
doi = "10.1016/S0014-2999(01)01196-7",
language = "English",
volume = "428",
pages = "277--286",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina

AU - Szabo, Marta E.

AU - Haines, David

AU - Garay, Elizabeth

AU - Chiavaroli, Carlo

AU - Farine, Jean Claude

AU - Hannaert, Patrick

AU - Berta, A.

AU - Garay, Ricardo P.

PY - 2001/10/5

Y1 - 2001/10/5

N2 - Calcium dobesilate possesses antioxidant properties and protects against capillary permeability by reactive oxygen species in the rat peritoneal cavity, but whether a similar action can take place in the diabetic rat retina is unknown. We investigated the oral treatment of diabetic rats with calcium dobesilate on the prevention of free radical-mediated retinal injury induced by ischemia/reperfusion (90 min ischemia followed by 3 min and/or 24 h of reperfusion). Streptozotocin-induced diabetic rats were orally treated with 50 and 100 mg/kg of calcium dobesilate for 10 days (n = 12 in each group). In the first series of studies, calcium dobesilate was found to significantly reduce the maldistribution of ion content in diabetic ischemic/reperfused rat retina. Thus, in diabetic rats treated with 100 mg/kg/day calcium dobesilate, ischemia/reperfusion provoked: (i) 27.5% increase in retinal Na+ content compared to 51.8% in the vehicle-treated group (P <0.05), and (ii) 59.6% increase in retinal Ca2+ content compared to 107.1% in vehicle-treated animals (P <0.05). In the second series of studies, calcium dobesilate was found to significantly protect diabetic rat retina against inhibition of Na+/K+-ATPase and Ca2+/Mg2+-ATPase activities by ischemia/reperfusion (54% and 41% reduction, respectively, with 100 mg/kg of calcium dobesilate) and also against changes in retinal ATP, reduced glutathione (GSH), and oxidized glutathione (GSSG) contents. In the third series of experiments, rats treated with 100 mg/kg of calcium dobesilate reduced the hydroxyl radical signal intensity to 41% (measured by electron paramagnetic resonance), induced by ischemia/reperfusion in diabetic rat retina. Finally, 100 mg/kg calcium dobesilate significantly reduced retinal edema (measured by the thickness of the inner plexiform layer) in diabetic rats. In conclusion, oral treatment with calcium dobesilate significantly protected diabetic rat retina against oxidative stress induced by ischemia/reperfusion. Whether the antioxidant properties of calcium dobesilate explain, at least in part, its beneficial therapeutic effects in diabetic retinopathy deserves further investigation.

AB - Calcium dobesilate possesses antioxidant properties and protects against capillary permeability by reactive oxygen species in the rat peritoneal cavity, but whether a similar action can take place in the diabetic rat retina is unknown. We investigated the oral treatment of diabetic rats with calcium dobesilate on the prevention of free radical-mediated retinal injury induced by ischemia/reperfusion (90 min ischemia followed by 3 min and/or 24 h of reperfusion). Streptozotocin-induced diabetic rats were orally treated with 50 and 100 mg/kg of calcium dobesilate for 10 days (n = 12 in each group). In the first series of studies, calcium dobesilate was found to significantly reduce the maldistribution of ion content in diabetic ischemic/reperfused rat retina. Thus, in diabetic rats treated with 100 mg/kg/day calcium dobesilate, ischemia/reperfusion provoked: (i) 27.5% increase in retinal Na+ content compared to 51.8% in the vehicle-treated group (P <0.05), and (ii) 59.6% increase in retinal Ca2+ content compared to 107.1% in vehicle-treated animals (P <0.05). In the second series of studies, calcium dobesilate was found to significantly protect diabetic rat retina against inhibition of Na+/K+-ATPase and Ca2+/Mg2+-ATPase activities by ischemia/reperfusion (54% and 41% reduction, respectively, with 100 mg/kg of calcium dobesilate) and also against changes in retinal ATP, reduced glutathione (GSH), and oxidized glutathione (GSSG) contents. In the third series of experiments, rats treated with 100 mg/kg of calcium dobesilate reduced the hydroxyl radical signal intensity to 41% (measured by electron paramagnetic resonance), induced by ischemia/reperfusion in diabetic rat retina. Finally, 100 mg/kg calcium dobesilate significantly reduced retinal edema (measured by the thickness of the inner plexiform layer) in diabetic rats. In conclusion, oral treatment with calcium dobesilate significantly protected diabetic rat retina against oxidative stress induced by ischemia/reperfusion. Whether the antioxidant properties of calcium dobesilate explain, at least in part, its beneficial therapeutic effects in diabetic retinopathy deserves further investigation.

KW - (Rat)

KW - Antioxidant

KW - Ca

KW - Calcium dobesilate

KW - Diabetic retinopathy

KW - Ischemia

KW - K

KW - Na

KW - Reperfusion

KW - Retina

UR - http://www.scopus.com/inward/record.url?scp=0035812665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035812665&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(01)01196-7

DO - 10.1016/S0014-2999(01)01196-7

M3 - Article

VL - 428

SP - 277

EP - 286

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2

ER -